PANC-1 tumor-associated antigens (PANC-1 TAAs)

PANC-1 tumor-associated antigens (TAAs) represent a heterogeneous collection of proteins, glycoproteins, and other molecules expressed by the PANC-1 human pancreatic ductal adenocarcinoma cell line. PANC-1 is a widely utilized model in oncology research, and its antigens, such as Mesothelin (MSLN), MUC1, and Carcinoembryonic Antigen (CEA), are frequently investigated as therapeutic targets (Montemagno et al., 2020; Kaur et al., 2013). These antigens play significant roles in the biological behavior of pancreatic cancer, including cell proliferation, adhesion, and the evasion of immune surveillance (Schnurr et al., 2002). In immunotherapy, PANC-1 TAAs are often used collectively, such as in the form of cell lysates to pulse dendritic cells, creating polyvalent vaccines designed to stimulate a broad anti-tumor immune response (Su et al., 2012). Individual components of the PANC-1 antigenic profile are also targeted by more specific modalities like CAR-T cells and monoclonal antibodies (Morello et al., 2016). However, because this term describes a collection of antigens rather than a single molecular entity, it presents challenges for standardized drug development and regulatory classification. Safety concerns primarily involve potential off-target effects on healthy tissues that share expression of these antigens, as well as the immunosuppressive nature of the pancreatic tumor microenvironment (Sadelain et al., 2017).

Other names

PANC-1 antigensPANC-1 cell line antigensPancreatic adenocarcinoma cell line 1 antigensPANC-1 cell-derived antigens

Induction of a polyvalent immune response against multiple tumor-specific epitopes expressed by the PANC-1 cell line.